Vhcp Management Ii 13F annual report
Vhcp Management Ii is an investment fund managing more than $379 million ran by David Stepp. There are currently 20 companies in Mr. Stepp’s portfolio. The largest investments include 10x Genomics Inc. and Axsome Therapeutics, together worth $217 million.
$379 million Assets Under Management (AUM)
As of 7th October 2020, Vhcp Management Ii’s top holding is 1,786,431 shares of 10x Genomics Inc. currently worth over $136 million and making up 35.9% of the portfolio value.
In addition, the fund holds 785,981 shares of Axsome Therapeutics worth $81.2 million, whose value grew 14.7% in the past six months.
The third-largest holding is Constellation Pharmaceuticals worth $70.7 million and the next is Biohaven Pharmaceuticals worth $25.2 million, with 462,903 shares owned.
Currently, Vhcp Management Ii's portfolio is worth at least $379 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Vhcp Management Ii
The Vhcp Management Ii office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, David Stepp serves as the Authorized Signatory at Vhcp Management Ii.
Recent trades
In the most recent 13F filing, Vhcp Management Ii revealed that it had opened a new position in
IVERIC bio and bought 1,004,299 shares worth $8.62 million.
This means they effectively own approximately 0.1% of the company.
IVERIC bio makes up
4.0%
of the fund's Health Care sector allocation and has grown its share price by 496.0% in the past year.
The investment fund also strengthened its position in Constellation Pharmaceuticals by buying
773,954 additional shares.
This makes their stake in Constellation Pharmaceuticals total 1,500,631 shares worth $70.7 million.
Constellation Pharmaceuticals soared 148.6% in the past year.
On the other hand, there are companies that Vhcp Management Ii is getting rid of from its portfolio.
Vhcp Management Ii closed its position in Ascendis Pharma A/S on 13th February 2020.
It sold the previously owned 234,591 shares for $22.6 million.
David Stepp also disclosed a decreased stake in Axsome Therapeutics by 0.1%.
This leaves the value of the investment at $81.2 million and 785,981 shares.
One of the average hedge funds
The two most similar investment funds to Vhcp Management Ii are Greatmark Investment Partners, Inc and Fiduciary Financial Services Of The Southwest Inc tx. They manage $380 million and $380 million respectively.
David Stepp investment strategy
Vhcp Management Ii’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 56.6% of
the total portfolio value.
The fund focuses on investments in the United States as
70.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
5% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $785 million.
The complete list of Vhcp Management Ii trades based on 13F SEC filings
These positions were updated on February 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| 10x Genomics Inc. |
No change
1,786,431
|
$136,215,000 | 35.91% |
| Axsome Therapeutics, Inc. |
11.98%
785,981
|
$81,239,000 | 21.42% |
| Constellation Pharmaceuticals, Inc. |
106.51%
1,500,631
|
$70,695,000 | 18.64% |
| Biohaven Pharmaceuticals |
35.07%
462,903
|
$25,200,000 | 6.64% |
| Ascendis Pharma A/S |
Closed
234,591
|
$22,596,000 | |
| Ra Pharmaceuticals |
Closed
677,164
|
$16,015,000 | |
| Shockwave Medical, Inc. |
55.32%
288,838
|
$12,686,000 | 3.34% |
| IVERIC bio, Inc. |
Opened
1,004,299
|
$8,617,000 | 2.27% |
| BioCryst Pharmaceuticals, Inc. |
Closed
2,874,602
|
$8,236,000 | |
| KalVista Pharmaceuticals, Inc. |
2.82%
366,268
|
$6,523,000 | 1.72% |
| ObsEva SA |
30.14%
1,573,639
|
$6,011,000 | 1.58% |
| Mersana Therapeutics, Inc. |
Opened
922,514
|
$5,286,000 | 1.39% |
| Kiniksa Pharmaceuticals Ltd. |
Closed
540,461
|
$4,599,000 | |
| La Jolla Pharmaceuticals |
Closed
518,102
|
$4,559,000 | |
| Spero Therapeutics, Inc. |
No change
474,015
|
$4,558,000 | 1.20% |
| Relmada Therapeutics, Inc. |
Opened
114,876
|
$4,480,000 | 1.18% |
| Adverum Biotechnologies, Inc. |
Opened
383,620
|
$4,419,000 | 1.16% |
| Tricida, Inc. |
Closed
118,886
|
$3,670,000 | |
| Marinus Pharmaceuticals, Inc. |
No change
1,486,676
|
$3,211,000 | 0.85% |
| Forty Seven Inc |
Opened
77,714
|
$3,060,000 | 0.81% |
| Milestone Pharmaceuticals, Inc. |
No change
148,560
|
$2,378,000 | 0.63% |
| NextCure, Inc. |
Opened
36,249
|
$2,042,000 | 0.54% |
| Myovant Sciences Ltd. |
Opened
76,768
|
$1,191,000 | 0.31% |
| 89bio, Inc. |
Opened
41,235
|
$1,084,000 | 0.29% |
| Radius Health, Inc. |
Closed
13,667
|
$352,000 | |
| Bellerophon Therapeutics, Inc. |
84.12%
659,087
|
$230,000 | 0.06% |
| Protagonist Therapeutics, Inc. |
92.45%
32,211
|
$227,000 | 0.06% |
| Proteostasis Therapeutics, Inc. |
Closed
130,733
|
$110,000 | |
| Prevail Therapeutics, Inc. |
Closed
2,604
|
$32,000 | |
| No transactions found | |||
| Showing first 500 out of 29 holdings | |||
Hedge funds similar to Vhcp Management Ii
- Private Capital Management
- Evermay Wealth Management
- Cornerstone Advisory
- Clear Creek Management
- Greenwood Gearhart Inc
- Fiduciary Financial Services Of The Southwest Inc tx
- Greatmark Investment Partners, Inc
- Royal Fund Management
- Fcg Advisors
- Arthur M. Cohen & Associates
- Phh Investments
- Mangrove Partners
- Parkside Investments
- Decatur Capital Management